Van de Wyngaert, Z., Carpentier, B., Pascal, L., Lionne‐Huyghe, P., Leduc, I., Srour, M., Vasseur, M., Demarquette, H., Terriou, L., Herbaux, C., Manier, S., Bossard, J., Barbieux, S., Chauvet, P., Willaume, A., Nudel, M., Bories, C., Gibier, J., Facon, T., & Boyle, E. M. (2020). daratumumab is effective in the relapsed or refractory systemic light‐chain amyloidosis but associated with high infection burden in a frail real‐life population. British journal of haematology, 188, e24–e27. http://access.bl.uk/ark:/81055/vdc_100099366722.0x000060